High Neutrophil/Lymphocyte Ratios in Symptomatic Pediatric COVID-19 Patients
To investigate the symptoms and laboratory results of children hospitalised with the diagnosis of COVID-19, aiming to reveal the characteristics of symptomatic cases. A descriptive cross-sectional study. Department of Pediatrics, Kastamonu Training and Research Hospital, Kastamonu, Turkey from March...
Gespeichert in:
Veröffentlicht in: | Journal of the College of Physicians and Surgeons--Pakistan 2021-07, Vol.31 (7), p.S93-S98 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | To investigate the symptoms and laboratory results of children hospitalised with the diagnosis of COVID-19, aiming to reveal the characteristics of symptomatic cases.
A descriptive cross-sectional study.
Department of Pediatrics, Kastamonu Training and Research Hospital, Kastamonu, Turkey from March to December 2020.
Seventy-nine children, hospitalised with the diagnosis of COVID-19, were included in the study and were divided into two groups as symptomatic and asymptomatic. The demographic data, laboratory results and clinics of the patients of the two groups were compared.
The mean age of participants was 10.43 ± 5.91 (0-17) years, and 57% (n=45) of them were girls. Five patients in the symptomatic group had comorbidities (2 allergic asthma, cerebral palsy, type-1 diabetes mellitus and anorexia nervosa). The most common symptom was fever (36.7%, n=29). It was noteworthy that everyone with an NLR >3.13 (high-NLR) was symptomatic. Significantly more patients in the high-NLR group were symptomatic compared with the low-NLR group (p=0.005). On the other hand, symptomatic children had significantly higher levels of C-reactive protein (2.8 (IQR: 1.2-10.0) mg/L vs. 1.4 (IQR: 0.4-2.0) mg/L, p=0.011); and procalcitonin (0.05 (IQR: 0.02-0.10) ng/mL vs. 0.01 (IQR: 0.00-0.03) ng/mL, p |
---|---|
ISSN: | 1022-386X 1681-7168 |
DOI: | 10.29271/jcpsp.2021.Supp2.S93 |